Genetic Epidemiology, Psychiatric Genetics, Asthma Genetics and Statistical Genetics Laboratories investigate the pattern of disease in families, particularly identical and non-identical twins, to assess the relative importance of genes and environment in a variety of important health problems.
QIMR Home Page
GenEpi Home Page
Publications
Contacts
Research
Staff Index
Collaborators
Software Tools
Computing Resources
Studies
Search
GenEpi Intranet
PMID
15904951
TITLE
BRAF polymorphisms and the risk of ovarian cancer of low malignant potential.
ABSTRACT
OBJECTIVE NlmCategory: OBJECTIVE
The object of this study was to test the hypothesis that BRAF is a low-risk susceptibility gene for low malignant potential (LMP) ovarian cancer. A recent study of the relationship between BRAF polymorphisms and malignant melanoma identified strong linkage disequilibrium across the BRAF gene with one of the three most common haplotypes (haplotype C) having a population attributable risk of approximately 1.6%. We therefore hypothesized that the same BRAF haplotype may confer an increased risk of serous ovarian tumors of low malignant potential.
METHODS NlmCategory: METHODS
We genotyped 383 cases of LMP ovarian cancer, including 234 of serous histology, and 987 controls for seven SNPs, representative of the most common BRAF gene haplotypes, using MALDI-TOF mass spectrometry.
RESULTS NlmCategory: RESULTS
Haplotype information was obtained for 369 LMP ovarian cancer cases and 983 healthy controls. None of the haplotypes were found to be associated with risk of LMP ovarian cancer (OR for haplotype C 0.81, 95% CI = 0.54-1.22), or with the risk of serous LMP ovarian cancer (OR for haplotype C 0.90, 95% CI = 0.56-1.45).
CONCLUSION NlmCategory: CONCLUSIONS
We found no evidence to suggest that BRAF is a low-risk LMP ovarian cancer susceptibility gene.
DATE PUBLISHED
2005 Jun
HISTORY
PUBSTATUS PUBSTATUSDATE
received 2004/10/28
revised 2005/03/02
accepted 2005/03/09
pubmed 2005/05/21 09:00
medline 2005/08/12 09:00
entrez 2005/05/21 09:00
AUTHORS
NAME COLLECTIVENAME LASTNAME FORENAME INITIALS AFFILIATION AFFILIATIONINFO
Kelemen L Kelemen Livia L Queensland Institute of Medical Research, 300 Herston Rd, Herston, QLD 4006, Australia.
James M James Michael M
Spurdle A Spurdle Amanda A
Campbell I Campbell Ian I
Chang-Claude J Chang-Claude Jenny J
Peel D Peel David D
Anton-Culver H Anton-Culver Hoda H
Berchuck A Berchuck Andrew A
Schildkraut J Schildkraut Joellen J
Whittemore A Whittemore Alice A
McGurie V McGurie Valerie V
DiCioccio RA DiCioccio Richard A RA
Duffy D Duffy David D
Chenevix-Trench G Chenevix-Trench Georgia G
INVESTIGATORS
JOURNAL
VOLUME: 97
ISSUE: 3
TITLE: Gynecologic oncology
ISOABBREVIATION: Gynecol. Oncol.
YEAR: 2005
MONTH: Jun
DAY:
MEDLINEDATE:
SEASON:
CITEDMEDIUM: Print
ISSN: 0090-8258
ISSNTYPE: Print
MEDLINE JOURNAL
MEDLINETA: Gynecol Oncol
COUNTRY: United States
ISSNLINKING: 0090-8258
NLMUNIQUEID: 0365304
PUBLICATION TYPE
PUBLICATIONTYPE TEXT
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
COMMENTS AND CORRECTIONS
GRANTS
GRANTID AGENCY COUNTRY
1-R01-CA76016 NCI NIH HHS United States
CA-058860 NCI NIH HHS United States
CA-78134 NCI NIH HHS United States
CA16056 NCI NIH HHS United States
CA71966 NCI NIH HHS United States
GENERAL NOTE
KEYWORDS
MESH HEADINGS
DESCRIPTORNAME QUALIFIERNAME
Adult
Aged
Aged, 80 and over
Case-Control Studies
Cystadenocarcinoma, Serous pathology
Female pathology
Genetic Predisposition to Disease pathology
Haplotypes pathology
Humans pathology
Middle Aged pathology
Ovarian Neoplasms pathology
Polymorphism, Single Nucleotide pathology
Proto-Oncogene Proteins B-raf genetics
SUPPLEMENTARY MESH
GENE SYMBOLS
CHEMICALS
REGISTRYNUMBER NAMEOFSUBSTANCE
EC 2.7.11.1 BRAF protein, human
EC 2.7.11.1 Proto-Oncogene Proteins B-raf
OTHER ID's